Hematological MalignancyHALTAging-1NCT07292272
Halt Aging in Survivors of Blood Cancers
A study testing Behavioral Coaching Intervention and Virtual Exercise Platform in people with Hematological Malignancy and Leukemia, run by University of Nebraska at 1 site in United States.
Trial summary
Older survivors of blood cancer are at a high risk of accelerated biological aging, which increases their risk of developing multiple aging-related conditions. Whereas physical exercise can improve overall health, older cancer survivors do not meet the recommended physical activity, highlighting the need to develop… Read more about this study
- Who is it for?
- Ages 50 years and older
- Conditions the study is for
- Hematological Malignancy, Leukemia, Lymphoid Leukemia
- What is being tested?
- Behavioral Coaching Intervention and Virtual Exercise Platform
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 180 participants
- Where
- 1 siteUnited States
- Study dates
- 9 Apr 2026to 25 Mar 2033
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥50 years
- A history of hematological malignancy
- Participants must be able to and willingly give informed consent
Who cannot join
- Patients receiving intensive induction or consolidation chemotherapy. Maintenance chemotherapy, or lower-intensity chemotherapy for an indolent hematological malignancy is allowed.
- Neurodegenerative disease (e.g. Alzheimer's dementia), stroke, or uncontrolled psychotic disorders (e.g. schizophrenia or bipolar disorder) in the past 3 months if those disorders are considered significant enough to impair participation in the study.
- Illnesses such as clinical evidence of decompensated heart failure, unstable angina, or orthopedic or neuromuscular disorders that could limit safe participation in aerobic exercise.
- Cardiopulmonary exercise test results that preclude safe exercise (e.g., life-threatening arrhythmia, balance difficulties, peak VO2 <10 ml/kg/min).
- Estimated life expectancy of less than 6 months (that precludes assessment of study primary endpoint).
- Self-reported pregnancy or the possibility of pregnancy.
- Participants who do not plan to follow up at the participating center.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
University of Nebraska Medical Center
Omaha, Nebraska, 68008
IIT Office IIT Office, 402-559-4596, IITOffice@unmc.edu
Vijaya Bhatt, MBBS
About this study
Official title: Halt Aging in Survivors of Blood Cancers: the HALTAging-1 Study
Older survivors of blood cancer are at a high risk of accelerated biological aging, which increases their risk of developing multiple aging-related conditions. Whereas physical exercise can improve overall health, older cancer survivors do not meet the recommended physical activity, highlighting the need to develop behavioral interventions to increase adherence. Several other knowledge gaps exist to implement exercise interventions in older survivors of blood cancer; the dose and duration of exercise necessary to slow biological aging in older blood cancer survivors remain unknown. To bridge these gaps in knowledge, we have designed a Phase 2 randomized control trial to test the effects of behavioral and exercise interventions on various outcomes.
- Conditions
- Hematological Malignancy, Leukemia, Lymphoid Leukemia, Multiple Myeloma, Myeloid Leukemia, Monocytic Leukemia
- Being tested
- Behavioral Coaching Intervention, Virtual Exercise Platform
- Keywords
- Hodgkin Lymphoma, Leukemia, Lymphoid Leukemia, Multiple Myeloma, Myeloid Leukemia, Monocytic Leukemia, Non-hodgkin Lymphoma, Other Hematologic Condition, Epigenetic clock, Biological aging, Quality of life, Blood cancer survivors
- Medical subject headings
- Hematologic Neoplasms, Leukemia, Leukemia, Lymphoid, Multiple Myeloma, Leukemia, Myeloid, Leukemia, Monocytic, Acute, Lymphoma, Non-Hodgkin, Hodgkin Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Behavioral Coaching InterventionBehavioural
Intervention arm incorporating virtually supervised moderate-intensity aerobic exercise and behavioral intervention/coaching to improve adherence
Virtual Exercise PlatformBehavioural
Access to a virtual exercise platform that provides exercise classes and educational sessions for older survivors of blood cancer
| Study group | Role | What they receive |
|---|---|---|
| Intervention Arm: Exercise + Behavioral Coaching | Experimental | Intervention arm incorporating virtually supervised moderate-intensity aerobic exercise and behavioral intervention/coaching to improve adherence Receives: Behavioral: Behavioral Coaching Intervention; Behavioral: Virtual Exercise Platform |
| Enhanced Usual Care-Virtual Gym | Active comparator | Participants will receive access to a virtual exercise platform, and educational sessions but will not receive behavioral coaching Receives: Behavioral: Virtual Exercise Platform |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of participants who adhered to the exercise regimen at 6-months post enrollment.
Participants achieving at least 120 minutes per week of moderate-intensity aerobic exercise, measured using Polar heart rate monitor data and exercise diaries.
Measured: 6 Months from start of program
Percentage of participants who adhered to the exercise regimen at 12-months post enrollment.
Participants achieving at least 120 minutes per week of moderate-intensity aerobic exercise, measured using Polar heart rate monitor data and exercise diaries to assess sustainability of adherence.
Measured: 12 Months from start of program.
Secondary outcomes (1)
Physical Function (6- Minute Walk Test Distance)
Distance covered during the 6-minute walk test (6MWT) to assess physical function.
Measured: 6 months from randomization
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Dec 2025
- Study start9 Apr 2026
- Primary completion25 Mar 2032 (estimated)
- Study completion25 Mar 2033 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hematological MalignancyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 180 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Nebraska
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Vijaya Raj Bhatt, MBBS,MS, Principal investigator, University of Nebraska
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07292272
- Sponsor's protocol ID
- 606-25-FB
- Acronym
- HALTAging-1
- Status last verified
- Dec 2025
- First submitted
- 5 Dec 2025
- Last updated
- 1 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No